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1. ~t~duction 
Enkephalins, the endogenous opioid peptides: 
Tyr-Gly-Gly-Phe-Met and -Leu [ 11, have been 
known to show much higher agonist potency in the 
mouse vas deferens preparation (MVD) than in the 
guinea-pig leum assay system (GPI) [2-61. The high 
MVD/GPI potency ratio is characteristic of enke- 
phalins and of their synthetic analogs unless the pen- 
tapeptides are terminated by an amide function. For 
instance, potency ratios calculated for Met-enke- 
phalin, its D-Ala2 analog and [D-Ala2, Met’]-enke- 
ph~~ide were 9.0,8.4 and 2.0, respectively [2]. 
The MVDlGPI ratio for &endorphin, the 3 l-residue 
opioid peptide of the pituitary, is -1.2 and for non- 
peptide narcotics, e.g., normorphine and morphine 
even smaller [2,4-61. Accordingly, the acidic COOH 
group at the C-terminus i  essential for the ‘enke- 
phalinoid’ character of pentapeptides. Starting from 
this consideration we synthesized some analogs of 
norleucine (Nle)-enkephahn i  which the terminal 
COOH group is replaced by SOaH and POsH, group, 
respectively, i.e., Me’ is ~bstituted by a-amino- 
~nt~e-s~fonic acid (NleS) and ff-amino-pentane- 
phosphonic acid (MeP), respectively. The dissociation 
constant of a sulfonic acid or a phosphonic acid is 
known to be higher than that of the corresponding 
carboxylic acid. For instance, pKL values of taurine 
and p&nine are 1.5 and 3.6, respectively [7]. Sim- 
ilarly, pKH of glycine is 2.34 while the two pKH 
values of amino-methane-phosphonic acidare 1.85 
and 5.35, respectively [S]. The more acidic terminal 
groups were expected to improve the enkephalin-like 
activity of the peptides. To study this question the 
opiate agonist potencies of the new compounds were 
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compared to those of the parent peptides with ter- 
minal COOH function. 
2. Materials and methods 
Me’-enkephalin and its analogs containing D-Ala, 
D-Me or D-Met at position 2 and MeS, D-MeS, MeP 
or D-MeP at position 5 were prepared by the conven- 
tional synthesis n solution starting from Me, DL-MeS 
and DL-MeP, respectively. For obtaining DLMeS 
bisultite compound of ~-v~er~dehyde was reacted 
with excess ~monium hydroxide in water followed 
by acidification. DCMeP was obtained from its ben- 
zyloxycarbonyl(Z) derivative by hydrogenolysis. 
Z-DL-MeP was prepared by analogy with a known 
procedure [9]; i.e., by reacting benzyl carbamate, 
n-valeraldehyde and PCla in acetic acid. DLMeS and 
DL-MeP were acylated with N-protected L-phenyl- 
alanine by the mixed anhydride method. The diaster- 
eomeric mixture of dipeptides, i.e., phe-MeS/Phe- 
D-MeS and Phe-MeP~~e-D-MeP, respectively, 
obtained after deblock~g, were separated by crystalli- 
zation. Con~guration of MeS and MeP in the dipep 
tides was determined by the rule of shift, i.e., the 
optical rotation of the MeS- and MePdipeptides 
were compared with those of the corresponding Nle- 
dipeptides of known configuration. This assignment 
was in agreement with the results of digestion of 
NleS’-, D-Mess-, NleP’- and D-MeP’enkephalins 
with aminopeptidase M (Rohm GmbH). Enzyme sta- 
bility of these peptides was also examined against car- 
boxypeptidase A(Miles-Yeda). Details of the synthetic 
work were described in [lo]. The opiate agonist activ- 
ities of compounds were determ~ed in electrically 
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stimulated mouse vas deferens [6,1 l] and guinea-pig 
ileum [ 121 preparations. Antinociceptive properties 
were assessed by the rat tail-flick test [ 131 as in [ 141. 
3. Results and discussion 
The opiate agonist activities determined in MVD 
and GPI are summarized in table 1. The peptides 
involved in this study can be described by the general 
formula Tyr-Xxx-Gly-Phe-Yyy wherein Xxx 
stands for Gly, D-Ala, D-Nle or D-Met and Yyy for 
Nle, NleS, D-NleS, NleP and D-NleP. 
Replacement of Nle5 by NleS or NleP resulted in 
enhanced biological potency in general. In case of 
substitution by NleS these increments of activity 
were nearly equal both in the MVD preparation and 
in the GPI assay, thus the MVD/GPI ratios changed 
by <14-42%. Replacement by NleP increased poten- 
cies if the substituents atposition 2 were Gly, D-Ala 
and D-Nle, respectively, while diminished activities 
were found for the D-Met’ containing molecule. 
Higher potencies were obtained in MVD than in GPI. 
Similarly, in the case of D-Met’ analog the activity 
measured in MVD was lowered to a lesser extent than 
in GPI. Thus the bulky, dibasic POSH2 group at the 
‘C’-terminus seems to be preferred or tolerated by the 
6 receptors of MVD rather then by the ~1 receptors of 
GPI. As a consequence higher MVD/GPI potency 
ratios could be calculated for the NleP5 analogs than 
for the corresponding Nle5- or NleS’enkephalins. 
Replacement by D-NleS or D-NleP resulted in a 
substantial loss of agonist activities in particular of 
these measured in MVD. With an amino carboxylic 
acid at the C-terminus of enkephalins the influence of 
the configuration seems to be just the opposite. 
Namely [D-Ala’, D-Let?] -enkephalin was found to be 
3.times more active in MVD than its L-I.eu5 analog 
[2]. In the case of [D-Ala’, D-NleSS]-enkephalin a d 
its L-NleS’ isomer this potency ratio is 0.06. 
NleS’ - and NleP’ enkephalins containing D-amino 
acid residue at position 2 possess analgesic activity 
when giving them intracerebroventricularly. Of these 
[D-Met2, D-NleP’] enkephalin was the only compound 
Table 1 
Opioid agonist activities of enkephalin analogs Tyr-Xxx-Gly-Phe-Yyy in MVD and in GPI given in 
10-6/IC,, and their analgesic potencies relative to morphine (= 100) 
Tyr-Xxx-Gly-Phe-Yyy MVD 
10-6/Ic,a, 
GPI 
lO.“/IC,a, 
MVD 
GPI 
analgesic 
potencyb 
i.c.v. i.v. 
-Gly Me 48.49 (l)c 2.74 (l)c 17.7 - - 
-Gly MeS 235.89 (4.8) 16.99 (6.2) 13.9 2 2 
-Gly MeP 430.96 (8.9) 7.81 (2.8) 55.2 1 1 
-Gly D-MeS 5.48 (0.1) 0.27 (0.1) 20.3 2 2 
-D-Ala Me 1000.00 (1) 15.29 (1) 65.4 -’ - 
-D-Ala MeS 1786.03 42.81 41.7 2.0 2 
-D-Ala MePd 
(1.8) (2.8) 
5132.84 (5.1) 61.16 (4.0) 83.9 15.0 2 
-D-Ala D-MeSd 58.10 (0.06) 15.29 (1 .O) 3.8 9.8 2 
-D-Me Me 1077.24 (1) 16.78 (1) 64.2 - - 
-D-Me MeSd 4761.90 (4.4) 117.45 (7.0) 40.5 2 2 
-D-Me MeP 4221.19 (3.9) 26.84 (1.6) 157.3 4.5 2 
-D-Me D-MeS 10.07 (0.01) 8.39 (0.5) 1.2 2 2 
----D-Met- Med 1667.78 (1) 25.97 (1) 64.2 - - 
-D-Met---- MeS 2041.65 (1.2) 54.54 (2.1) 40.5 9.5 2 
-D-Met----- MeP 618.20 (0.4) 9.35 (0.4) 66.1 25.0 2 
-D-Met- D-MeS 5.19 (0.003) 10.39 (0.4) 0.5 6.4 2 
-D-Met----- D-MeP 7.53 (0.004) 10.65 (0.4) 0.7 52.0 16.8 
a Dimension is M-’ 
b ED,, values of morphine ln the tail-flick test in rats were 3.14 nmol/animal after intracerebroventricular 
(i.c.v.) administration and 1.9 pmol/kg after intravenous injection (i.v.) 
’ Changes in activity relative to the parent Nle5 analogs 
d The most active analogs of Nles- Mess-, D-NleS5- and NlePS-enkephaBns 
309 
Volume 117. number 1 FEBS LETTERS August 1980 
which caused ~t~o~iception after systemic admini- 
stration as well. 
Comparison of data given in table 1 also reveals 
that a signif%ant interdependence exists between 
residues 2 and 5 of enkephalins, which is manifested 
in the spade-receptor ~tera~tions either directly or 
through its contribution to the formation of preferen- 
tial conformation of the given molecule. The structure 
of analogs possessing the highest activities in vitro 
(marked by asterisks) how the most favourable com- 
bination of the studied residues at position 2 and 5, 
respectively, i.e., D-Ala-MeP, D-Ala-D-MeS, 
D-Me-MeS and D-Met-Me, respectively. However, 
as for the analgesic potency (i.c.v.) of MeS5- and 
MePs enkephahns, D-Met2 is the most prefered sub- 
stituent, which, regarding the in vitro potencies is a 
rather unfavourable one. Similar ~terrelations could 
also be observed in other groups of enkeph~ analogs 
WI. 
A further fact which was proved by this study is 
that peptides containing D- or LNleS or MeP as C-ter- 
minal residue were resistant towards carboxypeptidase 
A. Namely, only unchanged pentapeptides could be 
detected in the 2 h digest of Mess-, D-Mess-, MeP5- 
and D.MeP5~~eph~s while 6%70% of Me 
and Phe were released from Mes-enkephalin under 
identical conditions [16]. Thus, replacement of
COOH by SOsH or POsHa seems to be a tool for 
preparing carboxy~ptid~-resist~t peptides with 
acidic ‘C-terminal of ~onf~uration. 
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